1-15 of 15
Tim Demuth
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT154: Combination of cinrebafusp alfa with ramucirumab and paclitaxel is well tolerated and elicits encouraging clinical activity in patients with HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma

Geoffrey Ku, Jeeyun Lee, Kayti Aviano, Tim Demuth, Laura-Carolin Hasenkamp, Shane A. Olwill
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT154.
https://doi.org/10.1158/1538-7445.AM2023-CT154
Published: 14 April 2023
View articletitled, Abstract CT154: Combination of cinrebafusp alfa with ramucirumab and paclitaxel is well tolerated and elicits encouraging clinical activity in patients with HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma
Journal Articles

Abstract CT122: A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma and in combination with tucatinib in patients with HER2 low gastric or gastroesophageal junction (GEJ) adenocarcinoma

Sarina A. Piha-Paul, Mukul Gupta, Do-Youn Oh, Yeul Hong Kim, Sun Young Rha, Yoon-Koo Kang, Marc Diez Garcia, Tania Fleitas Kanonnikoff, Virginia Arrazubi Arrula, Kayti Aviano, Tim Demuth, Geoffrey Ku
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT122.
https://doi.org/10.1158/1538-7445.AM2022-CT122
Published: 15 June 2022
View articletitled, Abstract CT122: A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma and in combination with tucatinib in patients with HER2 low gastric or gastroesophageal junction (GEJ) adenocarcinoma
Journal Articles

Abstract CT255: Study of PRS-344/S095012 a PD-L1/4-1BB bispecific antibody-Anticalin®-fusion in patients with solid tumors

Christiane Jungels, Nuria Kotecki, Emiliano Calvo, Elena Garralda, Timothy Price, Xiaojiang Zahn, Atif Abbas, Lisa Mahnke, Winrich Rauschning, Aizea Morales-Kastresana, Lucia Pattarini, Birgit Bossenmaier, Alix Scholer-Dahirel, Tim Demuth, Julie Legrande
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT255.
https://doi.org/10.1158/1538-7445.AM2022-CT255
Published: 15 June 2022
View articletitled, Abstract CT255: Study of PRS-344/S095012 a PD-L1/4-1BB bispecific antibody-Anticalin®-fusion in patients with solid tumors
Journal Articles

Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer

Jan H. M. Schellens, Robin van Geel, Johanna C. Bendell, Anna Spreafico, Martin Schuler, Takayuki Yoshino, Jean-Pierre Delord, Yasuhide Yamada, Martijn P. Lolkema, Jason E. Faris, Ferry A. L. M. Eskens, Sunil Sharma, Rona Yaeger, Heinz-Josef Lenz, Zev A. Wainberg, Emin Avsar, Arkendu Chatterjee, Savina Jaeger, Tim Demuth, Josep Tabernero
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): CT136.
https://doi.org/10.1158/1538-7445.AM2015-CT136
Published: 01 August 2015
View articletitled, Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer
Journal Articles

Abstract 2969: A Wee1 kinase inhibitor, MK-1775, sensitizes cervical carcinoma cell lines to cisplatin and topotecan

Stuart D. Shumway, Jamie L. Kubica, Amy D. Guertin, Melissa S. Hurd, Roseanne S. Wexler, Tim Demuth, Carlo Toniatti
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 2969.
https://doi.org/10.1158/1538-7445.AM2011-2969
Published: 15 April 2011
View articletitled, Abstract 2969: A Wee1 kinase inhibitor, MK-1775, sensitizes cervical carcinoma cell lines to cisplatin and topotecan
Journal Articles

Abstract 3394: A gamma secretase inhibitor reduces large neurosphere formation in glioma cell lines which correlates with decreased tumorigenicity

Javier Lopez-Molina, Sudhir Rao, Minilik Angagaw, Roseanne Wexler, Razvan Cristescu, Tim Demuth, Hong Sun, Carlo Toniatti
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 3394.
https://doi.org/10.1158/1538-7445.AM2011-3394
Published: 15 April 2011
View articletitled, Abstract 3394: A gamma secretase inhibitor reduces large neurosphere formation in glioma cell lines which correlates with decreased tumorigenicity
Journal Articles

De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model

James W. Watters, Chun Cheng, Pradip K. Majumder, Ruojie Wang, Sireesha Yalavarthi, Carol Meeske, Lingxin Kong, Wenping Sun, Jie Lin, Joerg Heyer, Chris Ware, Christopher Winter, John F. Reilly, Tim Demuth, Steve Clark, M. Isabel Chiu, Murray O. Robinson, Nancy Kohl, Karuppiah Kannan
Journal: Cancer Research
Cancer Res (2009) 69 (23): 8949–8957.
https://doi.org/10.1158/0008-5472.CAN-09-1544
Published: 30 November 2009
View articletitled, De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model
Open the PDF for De novo Discovery of a γ-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model in another window
Includes: Supplementary data
Journal Articles

Abstract #3605: Phase I study of the Gamma Secretase Inhibitor MK-0752 in patients with metastatic breast and other advanced solid tumors

Patricia LoRusso, Tim Demuth, Elisabeth Heath, Lisa Malburg, Mary Jo Pilat, Santosh Kesari, Jason Russak, James Knowles, Robert Beckman, Lanyan Fang, Julie Stone, Ian Krop
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3605.
Published: 01 May 2009
View articletitled, Abstract #3605: Phase I study of the Gamma Secretase Inhibitor MK-0752 in patients with metastatic breast and other advanced solid tumors
Journal Articles

Mitogen Activated Protein Kinase Kinase 3 is up-regulated in cancer, drives the invasive phenotype, and predicts short survival.

Tim Demuth, Linsey Reavie, Jessica Rennert, Mitsutoshi Nakada, Satoko Nakada, Christian Beaudry, Dominique Hoelzinger, Armanda Henrichs, Erich Anderson, Wendy McDonough, Michael Berens
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 2147.
Published: 01 May 2007
View articletitled, Mitogen Activated Protein Kinase Kinase 3 is up-regulated in cancer, drives the invasive phenotype, and predicts short survival.
Journal Articles

Ephrin-B2 drives migration and invasion of glioma and predicts short term survival

Eric Anderson, Mitsutoshi Nakada, Tim Demuth, Satoko Nakada, Linsey Reavie, Kelsey Drake, Josh Niska, Michael Berens
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 3940.
Published: 01 May 2007
View articletitled, Ephrin-B2 drives migration and invasion of glioma and predicts short term survival
Journal Articles

MAP-ing glioma invasion: MKK3 and p38 are drivers of glioma invasion and predict patient survival

Tim Demuth, Linsey B. Reavie, Jessica L. Rennert, Mitsutoshi Nakada, Christian Beaudry, Domninique B. Hoelzinger, Satoko Nakada, Jean C. Zenklusen, Howard A. Fine, Thomas Mikkelsen, Michael E. Berens
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 827.
Published: 15 April 2006
View articletitled, MAP-ing glioma invasion: MKK3 and p38 are drivers of glioma invasion and predict patient survival
Journal Articles

Autotaxin in glioma: promoter of invasion and dis-adhesive factor

Dominique B. Hoelzinger, Mitsutoshi Nakada, Christian Beaudry, Tyler T. Rosensteel, Linsey B. Reavie, Tim Demuth, Michael E. Berens
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 828.
Published: 15 April 2006
View articletitled, Autotaxin in glioma: promoter of invasion and dis-adhesive factor
Journal Articles

Glioma invadomics - identification and validation of novel targets for glioma invasion in-vivo

Linsey B. Reavie, Tim Demuth, Dominique B. Hoelzinger, Jessica L. Rennert, Ruth Bristol, Satoko Nakada, Jean C. Zenklusen, Howard A. Fine, Thomas Mikkelsen, Michael E. Berens
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 434.
Published: 15 April 2006
View articletitled, Glioma invadomics - identification and validation of novel targets for glioma invasion in-vivo
Journal Articles

MAP2K3 and p38 are drivers of in vitro glioma invasion.

Tim Demuth, Jessica L. Rennert, Dominique B. Hoelzinger, Linsey B. Reavie, Christian Beaudry, Luigi Mariani, Michael E. Berens
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 68.
Published: 01 May 2005
View articletitled, MAP2K3 and p38 are drivers of in vitro glioma invasion.
Journal Articles

The role of Autotaxin in glioblastoma multiforme invasion.

Dominique B. Hoelzinger, Christian Beaudry, Tim Demuth, Luigi Mariani, Mitsutoshi Nakada, Michael E. Berens
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 59.
Published: 01 May 2005
View articletitled, The role of Autotaxin in glioblastoma multiforme invasion.